Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Cited by (1,018)

Items 101–200 of 1,018

1. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
   Yukio Hosomi, Satoshi Morita, Shunichi Sugawara, Terufumi Kato, Tatsuro Fukuhara, Akihiko Gemma, Kazuhisa Takahashi, Yuka Fujita, Toshiyuki Harada, Koichi Minato et al. · 2019 · Journal of Clinical Oncology
2. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
   Zhou, Caicun, Chen, Gongyan, Huang, Yunchao, Zhou, Jianying, Lin, LiZhu, Feng, Jifeng, Wang, Zhehai, Shu, Yongqian, Shi, Jianhua, Hu, Yi et al. · 2021 · The Lancet Respiratory Medicine
3. Immune checkpoint inhibitor–related dermatologic adverse events
   Amaris N. Geisler, Gregory S. Phillips, Dulce M. Barrios M.S, Jennifer Wu, Donald Y.M. Leung, Andrea Primiani Moy, Jeffrey A. Kern, Mario E. Lacouture · 2020 · Journal of the American Academy of Dermatology
4. Antiemetics: ASCO Guideline Update
   Paul Joseph Hesketh, Mark G. Kris, Ethan Basch, Kari Bohlke, Sally Yowell Barbour, Rebecca Anne Clark-Snow, Michael A. Danso, Kristopher E.B. Dennis, L. Lee Dupuis, Stacie B. Dusetzina et al. · 2020 · Journal of Clinical Oncology
5. Neoantigen Driven B Cell and CD4+ T Follicular Helper Cell Collaboration Promotes Robust Anti-Tumor CD8+ T Cell Responses
   Can Cui, Jiawei Wang, Eric Fagerberg, Ping-Min Chen, Kelli A. Connolly, Martina Damo, Julie F. Cheung, Tianyang Mao, Adnan S. Askari, Shuting Chen et al. · 2020 · Cell
6. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
   Rilan Bai, Zheng Lv, Dongsheng Xu, Jiuwei Cui · 2020 · Biomarker Research
7. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
   David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Ruth Bauman, Joe Yujiao Chang, Lucian R. Chirieac, Thomas Anthony D’Amico, Thomas J. Dilling, M.C. Dobelbower et al. · 2018 · Journal of the National Comprehensive Cancer Network
8. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
   Meng‐Ling Wu, Qianrui Huang, Yao Xie, Xuyi Wu, Hongbo Ma, Yiwen Zhang, Yong Xia · 2022 · Journal of Hematology & Oncology
9. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
   Makoto Nishio, Fabrice Barlési, Howard West, Simon Ball, Rodolfo Eduardo Bordoni, Manuel Cobo, Pascale Dubray‐Longeras, Jerome H. Goldschmidt, Silvia Novello, Francesco Orlandi et al. · 2020 · Journal of Thoracic Oncology
10. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study
    Johnson, Melissa L., Cho, Byoung Chul, Luft, Alexander, Alatorre-Alexander, Jorge, Geater, Sarayut Lucien, Laktionov, Konstantin, Kim, Sang-We, Ursol, Grygorii, Hussein, Maen, Lim, Farah Louise et al. · 2023 · Journal of Clinical Oncology
11. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
    Nasser H. Hanna, Bryan James Schneider, Sarah Temin, Sherman Baker, Julie Renee Brahmer, Peter M. Ellis, Laurie E. Gaspar, Rami Y. Haddad, Paul Joseph Hesketh, Dharamvir Jain et al. · 2020 · Journal of Clinical Oncology
12. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
    Fenghua Wang, Xiaoli Wei, Fenggong Wang, Nong Xu, Lin Shen, Guanghai Dai, Xianglin Yuan, Yawen Chen, S. Yang, Jiawei Shi et al. · 2019 · Annals of Oncology
13. The emerging role of epigenetic therapeutics in immuno-oncology
    Topper, Michael J., Vaz, Michelle, Marrone, Kristen A., Brahmer, Julie R., Baylin, Stephen B. · 2020 · Nature Reviews Clinical Oncology
14. Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors
    Karthik S. Suresh, Khinh Ranh Voong, Bairavi Shankar, Patrick M. Forde, David S. Ettinger, Kristen Ashley Marrone, Ronan Joseph Kelly, Christine L. Hann, Benjamin Philip Levy, Josephine Louella Feliciano et al. · 2018 · Journal of Thoracic Oncology
15. New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
    Shang‐Hung Chen, Jang‐Yang Chang · 2019 · International Journal of Molecular Sciences
16. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
    Qingyang Lei, Dan Wang, Kai Sun, Liping Wang, Yi Zhang · 2020 · Frontiers in Cell and Developmental Biology
17. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
    Éric Pujade-Lauraine, Keiichi Fujiwara, Jonathan Andrew Ledermann, Amit M. Oza, Rebecca Sophie Kristeleit, Isabelle Laure Ray-Coquard, Gary Edward Richardson, Cristiana Sessa, Kan Yonemori, Susana N. Banerjee et al. · 2021 · The Lancet Oncology
18. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
    Gao, Shugeng, Li, Ning, Gao, Shunyu, Xue, Qi, Ying, Jianming, Wang, Shuhang, Tao, Xiuli, Zhao, Jun, Mao, Yousheng, Wang, Bing et al. · 2020 · Journal of Thoracic Oncology
19. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
    Delvys Rodríguez‐Abreu, Steven Francis Powell, Maximilian Johannes Hochmair, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, Giovanna Speranza, Flávia De Angelis, Manuel Dómine, Susanna Yee-Shan Cheng et al. · 2021 · Annals of Oncology
20. Emergence of a High-Plasticity Cell State during Lung Cancer Evolution
    Nemanja Despot Marjanovic, Matan Hofree, Jason Earl Chan, David A. Canner, Katherine Wu, Marianna Trakala, Griffin G. Hartmann, Olivia C. Ghirardelli Smith, Jonathan Y. Kim, Kelly V. Evans et al. · 2020 · Cancer Cell
21. Engineered T Cell Therapy for Cancer in the Clinic
    Lijun Zhao, Yu J Cao · 2019 · Frontiers in Immunology
22. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
    Heng‐Huan Lee, Ying‐Nai Wang, Weiya Xia, Chia‐Hung Chen, Kun-Ming Rau, Leiguang Ye, Yongkun Wei, Chao‐Kai Chou, Shao‐Chun Wang, Meisi Yan et al. · 2019 · Cancer Cell
23. Paradigms on Immunotherapy Combinations with Chemotherapy
    Diego Salas‐Benito, José Luis Perez‐Gracia, Mariano Ponz‐Sarvisé, Maria Esperanza Rodriguez-Ruiz, Iván Martínez‐Forero, Eduardo Castañón Álvarez, José María López-Picazo, Miguel F. Sanmamed, Ignacio Melero · 2021 · Cancer Discovery
24. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study
    Cortazar, Frank B., Kibbelaar, Zoe A., Glezerman, Ilya G., Abudayyeh, Ala, Mamlouk, Omar, Motwani, Shveta S., Murakami, Naoka, Herrmann, Sandra M., Manohar, Sandhya, Shirali, Anushree C. et al. · 2020 · Journal of the American Society of Nephrology
25. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
    Schoenfeld, A.J., Arbour, K.C., Rizvi, H., Iqbal, A.N., Gadgeel, S.M., Girshman, J., Kris, M.G., Riely, G.J., Yu, H.A., Hellmann, M.D. · 2019 · Annals of Oncology
26. Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
    Ugo Testa, Germana Castelli, Elvira Pelosi · 2018 · Cancers
27. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Kai Fu, Fachao Xie, Fang Wang, Liwu Fu · 2022 · Journal of Hematology & Oncology
28. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer
    Vanguri, Rami S., Luo, Jia, Aukerman, Andrew T., Egger, Jacklynn V., Fong, Christopher J., Horvat, Natally, Pagano, Andrew, Araujo-Filho, Jose de Arimateia Batista, Geneslaw, Luke, Rizvi, Hira et al. · 2022 · Nature Cancer
29. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
    Shun Lü, Wei Zhang, Lin Wu, Wenxiang Wang, Peng Zhang, Neotorch Investigators, Wentao Fang, Wenqun Xing, Qixun Chen, Lin Yang et al. · 2024 · JAMA
30. T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
    Jonathan Trujillo, Randy F. Sweis, Riyue Bao, Jason J. Luke · 2018 · Cancer Immunology Research
31. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions
    Liliang Xia, Yuanyong Liu, Ying Wang · 2019 · The Oncologist
32. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
    Wang, Jie, Lu, Shun, Yu, Xinmin, Hu, Yanping, Sun, Yuping, Wang, Zhijie, Zhao, Jun, Yu, Yan, Hu, Chunhong, Yang, Kunyu et al. · 2021 · JAMA Oncology
33. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
    Yang, Yunpeng, Wang, Zhehai, Fang, Jian, Yu, Qitao, Han, Baohui, Cang, Shundong, Chen, Gongyan, Mei, Xiaodong, Yang, Zhixiong, Ma, Rui et al. · 2020 · Journal of Thoracic Oncology
34. Advances in systemic therapy for non-small cell lung cancer
    Meagan Miller, Nasser H. Hanna · 2021 · BMJ
35. The Immunoscore: Colon Cancer and Beyond
    Helen K. Angell, Daniela Bruni, J. Carl Barrett, Ronald Herbst, Jérôme Galon · 2019 · Clinical Cancer Research
36. Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
    Biagio Ricciuti, Xinan Wang, Joao V. Alessi, Hira A. Rizvi, Navin R. Mahadevan, Yvonne Y. Li, Andrew Polio, James R. Lindsay, Renato Umeton, Rileen Sinha et al. · 2022 · JAMA Oncology
37. EGFR signaling pathway as therapeutic target in human cancers
    Elena Levantini, Giorgia Maroni, Marzia Del Re, Daniel Geoffrey Tenen · 2022 · Seminars in Cancer Biology
38. Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab
    Liu, Jingjing, Li, Shuang, Zhang, Shuang, Liu, Ying, Ma, Lixia, Zhu, Jing, Xin, Ying, Wang, Ying, Yang, Changliang, Cheng, Ying · 2019 · Journal of Clinical Laboratory Analysis
39. The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis
    Feng Li, Caichen Li, Xiuyu Cai, Zhanhong Xie, Liquan Zhou, Bo Cheng, Ran Zhong, Shan Xiong, Jianfu Li, Zhuxing Chen et al. · 2021 · EClinicalMedicine
40. Tumour burden and efficacy of immune-checkpoint inhibitors
    Dall’Olio, Filippo G., Marabelle, Aurélien, Caramella, Caroline, Garcia, Camilo, Aldea, Mihaela, Chaput, Nathalie, Robert, Caroline, Besse, Benjamin · 2022 · Nature Reviews Clinical Oncology
41. Immunotherapy in Lung Cancer: Current Landscape and Future Directions
    Hirva Mansurali Mamdani, Sandro Matosevic, Ahmed Bilal Khalid, Greg Andrew Durm, Shadia Ibrahim Jalal · 2022 · Frontiers in Immunology
42. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
    Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, Lieping Chen · 2022 · Nature Reviews Drug Discovery
43. Metal Drugs and the Anticancer Immune Response
    Englinger, Bernhard, Pirker, Christine, Heffeter, Petra, Terenzi, Alessio, Kowol, Christian R., Keppler, Bernhard K., Berger, Walter · 2019 · Chemical Reviews
44. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
    Jianchun Duan, Longgang Cui, Xiaochen Zhao, Hua Bai, Shangli Cai, Guoqiang Wang, Zhengyi Zhao, Jing Zhao, Shiqing Chen, Jia Song et al. · 2019 · JAMA Oncology
45. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
    Barzin Y. Nabet, Mohammad Shahrokh Esfahani, Everett James Moding, Emily G. Hamilton, Jacob J. Chabon, Hira A. Rizvi, Chloé Beate Steen, Aadel A. Chaudhuri, Chih Long Liu, Angela Bik‐Yu Hui et al. · 2020 · Cell
46. Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
    Zhao, Lin-Yong, Mei, Jia-Xin, Yu, Gang, Lei, Lei, Zhang, Wei-Han, Liu, Kai, Chen, Xiao-Long, Kołat, Damian, Yang, Kun, Hu, Jian-Kun · 2023 · Signal Transduction and Targeted Therapy
47. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
    Altorki, Nasser K, McGraw, Timothy E, Borczuk, Alain C, Saxena, Ashish, Port, Jeffrey L, Stiles, Brendon M, Lee, Benjamin E, Sanfilippo, Nicholas J, Scheff, Ronald J, Pua, Bradley B et al. · 2021 · The Lancet Oncology
48. Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
    Marek Z. Wojtukiewicz, Magdalena M. Rek, Kamil Karpowicz, Maria Górska, Barbara Polityńska, Anna M. Wojtukiewicz, Marcin Moniuszko, Piotr Radziwon, Stephanie C. Tucker, Kenneth V. Honn · 2021 · Cancer and Metastasis Reviews
49. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
    E.J. Aguilar, Biagio Ricciuti, Justin F. Gainor, Kenneth L. Kehl, Sasha Kravets, Suzanne Eleanor Dahlberg, Mizuki Nishino, Lynette Marie Sholl, Anika E. Adeni, Safiya J. Subegdjo et al. · 2019 · Annals of Oncology
50. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
    Chabanon, Roman M., Muirhead, Gareth, Krastev, Dragomir B., Adam, Julien, Morel, Daphné, Garrido, Marlène, Lamb, Andrew, Hénon, Clémence, Dorvault, Nicolas, Rouanne, Mathieu et al. · 2019 · Journal of Clinical Investigation
51. Immune evasion before tumour invasion in early lung squamous carcinogenesis
    Céline Mascaux, Mihaela Angelova, Angela Vasaturo, Jennifer Beane, Kahkeshan Hijazi, Geraldine Anthoine, Bénédicte Buttard, Françoise Rothé, Karen E Willard-Gallo, Annick Haller et al. · 2019 · Nature
52. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
    Sylvie Lantuéjoul, Ming‐Sound Tsao, Wendy A. Cooper, Nicolas Girard, Fred R. Hirsch, Anja Christiane Roden, Fernando López‐Ríos, Deepali Jain, Teh‐Ying Chou, Noriko Motoi et al. · 2019 · Journal of Thoracic Oncology
53. The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
    Matteo Berti, David Cortez, Massimo Lopes · 2020 · Nature Reviews Molecular Cell Biology
54. Development of Immunotherapy Combination Strategies in Cancer
    Timothy Anthony Yap, Eileen E. Parkes, Weiyi Peng, Justin Tyler Moyers, Michael A. Curran, Hussein A. Tawbi · 2021 · Cancer Discovery
55. Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
    Ricciuti, Biagio, Dahlberg, Suzanne E., Adeni, Anika, Sholl, Lynette M., Nishino, Mizuki, Awad, Mark M. · 2019 · Journal of Clinical Oncology
56. Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
    Joseph Nicholas Bodor, Yanis Boumber, Hossein Borghaei · 2019 · Cancer
57. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
    Minlin Jiang, Keyi Jia, Lei Wang, Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao, Yayi He, Caicun Zhou · 2021 · Acta Pharmaceutica Sinica B
58. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
    Hofmann, Marco H., Gerlach, Daniel, Misale, Sandra, Petronczki, Mark, Kraut, Norbert · 2022 · Cancer Discovery
59. Overcoming resistance to tumor-targeted and immune-targeted therapies
    Aldea, Mihaela, Andre, Fabrice, Marabelle, Aurelien, Dogan, Semih, Barlesi, Fabrice, Soria, Jean-Charles · 2021 · Cancer Discovery
60. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
    A.J. Schoenfeld, H. Rizvi, Chai Bandlamudi, Jennifer L. Sauter, William David Travis, Natasha Rekhtman, Andrew J. Plodkowski, Rocío Pérez-Johnston, Peter Sawan, Amanda Beras et al. · 2020 · Annals of Oncology
61. Evaluating eligibility criteria of oncology trials using real-world data and AI
    Ruishan Liu, Shemra Rizzo, Samuel Whipple, Navdeep Pal, Arturo López Pineda, Michael W. Lu, Brandon Arnieri, Ying Lü, William B. Capra, Ryan Copping et al. · 2021 · Nature
62. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)
    Zhou, Caicun, Wu, Lin, Fan, Yun, Wang, Zhehai, Liu, Lianke, Chen, Gongyan, Zhang, Li, Huang, Dingzhi, Cang, Shundong, Yang, Zhixiong et al. · 2021 · Journal of Thoracic Oncology
63. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
    Vernieri, Claudio, Fucà, Giovanni, Ligorio, Francesca, Huber, Veronica, Vingiani, Andrea, Iannelli, Fabio, Raimondi, Alessandra, Rinchai, Darawan, Frigè, Gianmaria, Belfiore, Antonino et al. · 2022 · Cancer Discovery
64. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer
    Joshua Michael Bauml, Rosemarie Mick, Christine Agnes Ciunci, Charu Aggarwal, Christiana W. Davis, Tracey L. Evans, Charuhas G. Deshpande, Linda Miller, Pooja Patel, Evan W. Alley et al. · 2019 · JAMA Oncology
65. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
    Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, R. Gervais, José Luis Perez‐Gracia, Ji‐Youn Han, Margarita Majem, Martin David Forster, I. Monnet et al. · 2021 · Journal of Thoracic Oncology
66. Lower Airway Dysbiosis Affects Lung Cancer Progression
    Tsay, Jun-Chieh J., Wu, Benjamin G., Sulaiman, Imran, Gershner, Katherine, Schluger, Rosemary, Li, Yonghua, Yie, Ting-An, Meyn, Peter, Olsen, Evan, Perez, Luisannay et al. · 2021 · Cancer Discovery
67. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer
    Hakozaki, Taiki, Richard, Corentin, Elkrief, Arielle, Hosomi, Yukio, Benlaïfaoui, Myriam, Mimpen, Iris, Terrisse, Safae, Derosa, Lisa, Zitvogel, Laurence, Routy, Bertrand et al. · 2020 · Cancer Immunology Research
68. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
    Luis G Paz-Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, Laszlo Urban, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio et al. · 2021 · Journal of Thoracic Oncology
69. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
    Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, Davit Giorgadze, Mikhail Vladimirovich Dvorkin, Konstantin Penkov, Константин Константинович Лактионов, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova et al. · 2022 · Nature Medicine
70. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
    Jonathan David Spicer, Marina Chiara Garassino, Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Ke‐Neng Chen, Christophe Dooms, Margarita Majem et al. · 2024 · The Lancet
71. Immunotherapeutic approaches for small-cell lung cancer
    Wade Thomas Iams, Jason Porter, Leora Horn · 2020 · Nature Reviews Clinical Oncology
72. Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors
    Fotis Nikolos, Kazukuni Hayashi, Xen Ping Hoi, Mark Ellie Alonzo, Qianxing Mo, Armine Kasabyan, Hideki Furuya, Jane Trepel, Dolores Di Vizio, Jlenia Guarnerio et al. · 2022 · Nature Communications
73. Clinical trial design in the era of precision medicine
    Elena Fountzilas, Apostolia Maria Tsimberidou, Henry Hiep Vo, Razelle Kurzrock · 2022 · Genome Medicine
74. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer
    Matthew Joseph Bott, Stephen C. Yang, Bernard J. Park, Prasad S. Adusumilli, Valerie W. Rusch, James M. Isbell, Robert J. Downey, Julie Renee Brahmer, Richard James Battafarano, Errol L. Bush et al. · 2018 · Journal of Thoracic and Cardiovascular Surgery
75. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors
    Harish Shanthanu Seethapathy, Sophia J. Zhao, Donald F. Chute, Leyre Zubiri, Yaa D. Oppong, Ian A. Strohbehn, Frank B. Cortazar, David E. Leaf, Meghan J. Mooradian, Alexandra–Chloé Villani et al. · 2019 · Clinical Journal of the American Society of Nephrology
76. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
    Bradley J. Monk, Nicoletta Colombo, Amit M. Oza, Keiichi Fujiwara, Michael J. Birrer, Leslie M. Randall, Elena V Poddubskaya, Giovanni Scambia, Yaroslav V. Shparyk, Myong Cheol Lim et al. · 2021 · The Lancet Oncology
77. Crizotinib-induced immunogenic cell death in non-small cell lung cancer
    Liu, Peng, Zhao, Liwei, Pol, Jonathan, Levesque, Sarah, Petrazzuolo, Adriana, Pfirschke, Christina, Engblom, Camilla, Rickelt, Steffen, Yamazaki, Takahiro, Iribarren, Kristina et al. · 2019 · Nature Communications
78. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval
    Bishal Gyawali, Spencer Phillips Hey, Aaron Seth Kesselheim · 2019 · JAMA Internal Medicine
79. Immuno-Oncology: Emerging Targets and Combination Therapies
    Henry T. Marshall, Mustafa B.A. Djamgoz · 2018 · Frontiers in Oncology
80. Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
    Petrelli, Fausto, Signorelli, Diego, Ghidini, Michele, Ghidini, Antonio, Pizzutilo, Elio Gregory, Ruggieri, Lorenzo, Cabiddu, Mary, Borgonovo, Karen, Dognini, Giuseppina, Brighenti, Matteo et al. · 2020 · Cancers
81. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
    James William Welsh, Hari Menon, Dawei Chen, Vivek Verma, Chad Z. Tang, Mehmet Altan, Kenneth R. Hess, Patricia M. de Groot, Quynh‐Nhu Nguyen, Rejani Varghese et al. · 2020 · Journal for ImmunoTherapy of Cancer
82. Targeting the DNA damage response in immuno-oncology: developments and opportunities
    Roman M. Chabanon, Mathieu Rouanne, Christopher J. Lord, Jean‐Charles Soria, Philippe Pasero, Sophie C. Postel-Vinay · 2021 · Nature reviews. Cancer
83. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
    Marie Kostine, Axel Finckh, Clifton O. Bingham, Karen Visser, Jan Leipe, Hendrik Schulze‐Koops, Ernest Choy, Karolina Benesova, Timothy R. D. J. Radstake, Andrew P. Cope et al. · 2020 · Annals of the Rheumatic Diseases
84. Immunotherapy, Inflammation and Colorectal Cancer
    Charles Robert Lichtenstern, Rachael Katie Ngu, Shabnam Shalapour, Michael Karin · 2020 · Cells
85. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
    Marcelo Vailati Negrao, Ferdinandos Skoulidis, Meagan Montesion, Katja Schulze, Ilze Bāra, Vincent Shen, Hao Xu, Sylvia Hu, Dawen Sui, Yasir Y. Elamin et al. · 2021 · Journal for ImmunoTherapy of Cancer
86. Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
    Conforti, Fabio, Pala, Laura, Bagnardi, Vincenzo, Viale, Giuseppe, De Pas, Tommaso, Pagan, Eleonora, Pennacchioli, Elisabetta, Cocorocchio, Emilia, Ferrucci, Pier Francesco, De Marinis, Filippo et al. · 2019 · JNCI: Journal of the National Cancer Institute
87. Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
    Christopher J. D. Wallis, Mohit Butaney, Raj Satkunasivam, Stephen J. Freedland, Sandip Pravin Patel, Omid Hamid, Sumanta Kumar Pal, Zachary William Abraham Klaassen · 2019 · JAMA Oncology
88. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
    Y.-L. Wu, D. Planchard, Shun Lü, Hao Sun, N. Yamamoto, Dongwook Kim, Daniel Shao-Weng Tan, James Chih‐Hsin Yang, M. Azrif, Tetsuya Mitsudomi et al. · 2018 · Annals of Oncology
89. Non-invasive decision support for NSCLC treatment using PET/CT radiomics
    Wei Mu, Lei Jiang, Jianyuan Zhang, Yu Shi, Jhanelle E. Gray, Ilke Tunali, Chao Gao, Yingying Sun, Jie Tian, Xinming Zhao et al. · 2020 · Nature Communications
90. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
    Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee, D.-W. Kim, Adnan M. Nagrial, Mark Voskoboynik, Hyun Cheol Chung, Kathryn Finch Mileham, Ulka N. Vaishampayan, Drew Warren Rasco et al. · 2021 · Annals of Oncology
91. Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
    Kelly Garneski Paulson, Valentin Voillet, Megan S. McAfee, Daniel S. Hunter, Felecia D. Wagener, Maurizio Perdicchio, William J. Valente, Samson Koelle, Candice D. Church, Natalie A. Vandeven et al. · 2018 · Nature Communications
92. Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine
    Zihang Chen, Li Lin, Chen‐Fei Wu, Chao‐Feng Li, Rui‐Hua Xu, Ying Hao Sun · 2021 · 癌症：英文版
93. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
    Lynette Marie Sholl, Fred R. Hirsch, David M. Hwang, Johan Botling, Fernando López‐Ríos, Lukas Bubendorf, Mari A. Mino-Kenudson, Anja Christiane Roden, Mary Beth Beasley, Alain Borczuk et al. · 2020 · Journal of Thoracic Oncology
94. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
    Lu, Shun, Wang, Jie, Yu, Yan, Yu, Xinmin, Hu, Yanping, Ai, Xinghao, Ma, Zhiyong, Li, Xingya, Zhuang, Wu, Liu, Yunpeng et al. · 2021 · Journal of Thoracic Oncology
95. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
    C.G. Kim, K.H. Kim, Kyoung‐Ho Pyo, C.-F. Xin, Min Hee Hong, Beung‐Chul Ahn, Y. Kim, Seong Jin Choi, Hong In Yoon, J.G. Lee et al. · 2019 · Annals of Oncology
96. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
    Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, José Luis Perez‐Gracia, Ji‐Youn Han, Catherine Dubos Arvis, Margarita Majem, Martin David Forster, I. Monnet et al. · 2020 · Journal of Clinical Oncology
97. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer
    Salma K. Jabbour, Ki Hyeong Lee, Nikolaj Frost, Valeriy Vladimirovich Breder, Dariusz Mirosław Kowalski, Theodore W. Pollock, E. Levchenko, Noemı́ Reguart, Alex Martínez‐Martí, Baerin Houghton et al. · 2021 · JAMA Oncology
98. Combined Magnetic Hyperthermia and Immune Therapy for Primary and Metastatic Tumor Treatments
    Jiong Pan, Ping Hu, Yuedong Guo, Junnian Hao, Dalong Ni, Yingying Xu, Qunqun Bao, Heliang Yao, Chenyang Wei, Qingsheng Wu et al. · 2020 · ACS Nano
99. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
    Solange Peters, Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma, T. Talbot, I. Monnet, Sandrine Hiret, P. Baas et al. · 2022 · Annals of Oncology
100. Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
     Fournel, Ludovic, Wu, Zherui, Stadler, Nicolas, Damotte, Diane, Lococo, Filippo, Boulle, Geoffroy, Ségal-Bendirdjian, Evelyne, Bobbio, Antonio, Icard, Philippe, Trédaniel, Jean et al. · 2019 · Cancer Letters